About Agenus (NASDAQ:AGEN)

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

When is Agenus' next earnings date?

What price target have analysts set for AGEN?

1 brokers have issued twelve-month price objectives for Agenus' shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Agenus' stock price to reach $7.00 in the next year. View Analyst Ratings for Agenus.

Has Agenus been receiving favorable news coverage?

News headlines about AGEN stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agenus earned a daily sentiment score of 0.15 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Millennium Management LLC, Candriam Luxembourg S.C.A. and Chicago Equity Partners LLC. Company insiders that have sold Agenus company stock in the last year include Alex Duncan, Christine M Klaskin and Karen Valentine. View Insider Buying and Selling for Agenus.

Which institutional investors are buying Agenus stock?

AGEN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., UBS Group AG, BlackRock Inc., Russell Investments Group Ltd., Northern Trust Corp, Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Agenus stock in the last two years include Corp Incyte, Garo H Armen and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.48.

How big of a company is Agenus?

Agenus has a market capitalization of $361.92 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]

MarketBeat Community Rating for Agenus (AGEN)

MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agenus (NASDAQ:AGEN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

1 Wall Street analysts have issued ratings and price targets for Agenus in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 101.73%. The high price target for AGEN is $7.00 and the low price target for AGEN is $7.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."